Effect of N-acetylcysteine treatment on the expression of leukocyte surface markers after burn injury.
Oxidative stress and inflammatory processes generate edema in burns. Treatment of consequent hypovolemia is a challenge. The aim of study was to assess if glutathione pro-drug N-acetylcysteine (NAC) can influence inflammation and fluid requirement. We also aimed to compare organ functions scores and vasoactive drug requirement. This prospective randomised study involved 28 patients with burn injury affecting more than 20% of body surface area. Fourteen patients were on standard therapy, whereas for other 14 patients NAC was supplemented. Blood samples were taken on admission and on the next five consecutive mornings. Leukocyte surface marker expressions were determined, multiple organ function scores, use of vasopressor agents and fluid requirements were recorded daily. Expression of CD11a (p < 0.05), CD18 (p < 0.05) and CD97 (p < 0.01) on the granulocytes were significantly lower in the NAC treated group, similarly to lymphocyte CD 49d (p < 0.05) and monocyte CD 49d (p < 0.01) and CD 97 (p < 0.05) expression. No significant difference was found in the fluid requirement between groups but patients the NAC group required less vasopressor and inotropic drugs from day 4. NAC treatment is associated with a less pronounced inflammation reflected in lower CD marker expression and vasopressor requirement.
Department of Anaesthesia and Intensive Care, Faculty of Medicine, University of Pécs, Pécs, Hungary. csaba.csontos@gmail.com
C
C
Csontos
B
B
Rezman
V
V
Foldi
L
L
Bogar
Z
Z
Bognar
L
L
Drenkovics
E
E
Röth
G
G
Weber
J
J
Lantos
D000111:Acetylcysteine / Q000494:pharmacology / Q000627:therapeutic use*; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism*; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D002056:Burns / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007962:Leukocytes / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009102:Multiple Organ Failure / Q000503:physiopathology; D018384:Oxidative Stress / Q000187:drug effects*; D011446:Prospective Studies
D015703:Antigens, CD; D000975:Antioxidants; D015415:Biomarkers; D000111:Acetylcysteine